DMIINasdaqBlank ChecksFiscal year ends December 31Also trades as DMIIR, DMIIU
Drugs Made In America Acquisition II Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$10.18−0.00 (-0.05%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.29 (+2.99%)since Dec 5, 2025
Weekly closes, adjusted for splits, on a log scale. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- $13.02M
Two years at a glance
Fiscal years 2024 to 2025 and trailing twelve months, USD
Operating income
-$635.24K
Net income
$13.02M
Reported periodTrailing twelve months